Terms: = Bone cancer AND PHOX2B, 8929 AND Prognosis
5 results:
1. Prospective investigation of applicability and the prognostic significance of bone marrow involvement in patients with neuroblastoma detected by quantitative reverse transcription PCR.
Druy AE; Shorikov EV; Tsaur GA; Popov AM; Zaychikov AN; Tuponogov SN; Saveliev LI; Tytgat GAM; Fechina LG
Pediatr Blood Cancer; 2018 Nov; 65(11):e27354. PubMed ID: 30007008
[TBL] [Abstract] [Full Text] [Related]
2. Expression of Five Neuroblastoma Genes in bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and prognosis.
Marachelian A; Villablanca JG; Liu CW; Liu B; Goodarzian F; Lai HA; Shimada H; Tran HC; Parra JA; Gallego R; Bedrossian N; Young S; Czarnecki S; Kennedy R; Weiss BD; Goldsmith K; Granger M; Matthay KK; Groshen S; Asgharzadeh S; Sposto R; Seeger RC
Clin Cancer Res; 2017 Sep; 23(18):5374-5383. PubMed ID: 28559462
[No Abstract] [Full Text] [Related]
3. phox2b is a suppressor of neuroblastoma metastasis.
Naftali O; Maman S; Meshel T; Sagi-Assif O; Ginat R; Witz IP
Oncotarget; 2016 Mar; 7(9):10627-37. PubMed ID: 26840262
[TBL] [Abstract] [Full Text] [Related]
4. Methylated RASSF1a is the first specific DNA marker for minimal residual disease testing in neuroblastoma.
Stutterheim J; Ichou FA; den Ouden E; Versteeg R; Caron HN; Tytgat GA; van der Schoot CE
Clin Cancer Res; 2012 Feb; 18(3):808-14. PubMed ID: 22142825
[TBL] [Abstract] [Full Text] [Related]
5. Multiple target molecular monitoring of bone marrow and peripheral blood samples from patients with localized neuroblastoma and healthy donors.
Corrias MV; Haupt R; Carlini B; Cappelli E; Giardino S; Tripodi G; Tonini GP; Garaventa A; Pistoia V; Pistorio A
Pediatr Blood Cancer; 2012 Jan; 58(1):43-9. PubMed ID: 21254375
[TBL] [Abstract] [Full Text] [Related]
